Similar articles

• Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

  Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M. Ellis MJ, et al. J Clin Oncol. 2001 Sep 15;19(18):3808-16. doi: 10.1200/JCO.2001.19.18.3808. J Clin Oncol. 2001. PMID: 11559718 Clinical Trial.
• Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.

  Altundag K, Altundag O. Altundag K, et al. J Clin Oncol. 2003 Dec 15;21(24):4656; author reply 4657. doi: 10.1200/JCO.2003.99.152. J Clin Oncol. 2003. PMID: 14673060 No abstract available.
• Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

  Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE. Dowsett M, et al. J Clin Oncol. 2005 Apr 10;23(11):2477-92. doi: 10.1200/JCO.2005.07.559. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767642 Clinical Trial.
• [Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].

  Zhang B. Zhang B. Zhonghua Zhong Liu Za Zhi. 2011 Apr;33(4):241-4. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 21575491 Review. Chinese. No abstract available.
• [Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].

  Lindberg H, Nielsen DL, Tuxen M, Kamby C. Lindberg H, et al. Ugeskr Laeger. 2007 Sep 10;169(37):3096-100. Ugeskr Laeger. 2007. PMID: 17877958 Review. Danish.